Bio X Cell
Founded in 1997, Bio X Cell specialises in the development and manufacture of monoclonal antibodies formulated specifically for in vivo research. The company focuses on functional antibodies that enable researchers to modulate biological pathways through blocking, neutralising, activating and cell-depleting mechanisms. Its reagents support preclinical studies across immunology, oncology, autoimmunity, infectious disease and neuroscience, as well as advanced in vitro systems including organoids and organ-on-chip models. Manufactured under stringent quality standards, Bio X Cell antibodies are designed to provide high purity, low endotoxin levels and consistent performance for studies investigating immune regulation, disease mechanisms and therapeutic targets.
The company’s portfolio includes the InVivoMAb™, InVivo Plus™, RecombiMAb™, InVivoSIM™ and Bispecific Antibody product families, alongside isotype controls, antibody fragments and custom antibody production services. These reagents support applications including pathway blockade, immune cell depletion, functional assays, flow cytometry, immunohistochemistry, ELISA and translational research. Bio X Cell also offers recombinant antibody engineering, conjugation services and large-scale antibody manufacturing to support research and development programmes.
Europa Biosite's subsidiaries distribute for Bio X Cell in Denmark, Estonia, Finland, Iceland, Ireland, Latvia, Lithuania, Norway, Sweden, Switzerland and the UK.